ATA Guidelines Tools

Source Ringel MD*, Sosa JA*, Baloch Z, Bischoff L, Bloom G, Brent GA, Brock PL, Chou R, Flavell RR, Goldner W, Grubbs EG, Haymart M, Larson SM, Leung AM, Osborne J, Ridge JA, Robinson B, Stewart DL, Rufano RP, and Wirth LJ. American yroid Association Differentiated yroid Cancer Guidelines Task Force. 2025 American yroid Association Management Guidelines for Adult Patients with Differentiated yroid Cancer. yroid 2025 Aug ;35(8):841-985. doi: 10.1177/10507256251363120 * Drs Ringel and Sosa were co-leaders of the task force and are co-first authors, contributing equally to the manuscript. American yroid Association Headquarters 2000 Duke Street, Suite 300 • Alexandria, VA 22314 Phone: 703.998.8890 • Fax: 703.998.8893 • www.thyroid.org Physician referral, patient resources available online in English and Spanish. Abbreviations 18 FDG-PET, 18F-fluorodeoxyglucose positron emission tomography; AJCC, American Joint Committee on Cancer; ATA, American yroid Association; ATC, advanced thyroid cancer; CBC, complete blood count; CLND, central lymph node dissection; CT, computed tomography; ctDNA, circulating tumor DNA; DATA, Diagnosis, Assessment, Treatment, Assessment; DTC, differentiated thyroid cancer; EBRT, external beam radiotherapy; EBSN, external branch of the superior laryngeal nerve; FNA, fine needle aspiration; FNMTC, familial non-medullary thyroid cancer; FTC, follicular thyroid carcinoma; GBq, gigabecquerels; HPF, high power fields; IEFVPTC, invasive encapsulated follicular variant of papillary thyroid carcinoma; IMA, immunometric assays; IMRT, intensity-modulated radiation therapy; LC/MSMS, liquid chromatography- tandem mass spectrometry; LT3, liothyronine; LT4, levothyroxine; MAPK, mitogen- activated protein kinase; mCi, millicuries; MKI, multikinase inhibitor; MRI, magnetic resonance imaging ; NIFTP, non-invasive follicular tumors with papillary-like nuclear features; NMTC, non-medullary thyroid cancer; NTRK, neurotrophic receptor tyrosine kinase; OTC, oncocytic thyroid carcinoma; PTC, papillary thyroid carcinoma; RAI, radioactive iodine; RAIR, radioactive iodine resistant; RFA, radiofrequency; rhTSH, recombinant human thyroid stimulating hormone; RLN, recurrent laryngeal nerve; ROR, risk of recurrence; SBRT, stereotactic body radiotherapy; SPECT, single-photon emission computed tomography; SPM, second primary malignancy; Tg, serum thyroglobulin; TgAb, serum thyroglobulin antibody; TGDCa, thyroid carcinoma arising within a thyroglossal duct; TRAE, treatment related adverse events; TSH, thyroid stimulating hormone; WBS, whole body scan Disclaimer is resource is for informational purposes only, intended as a quick-reference tool based on the cited source guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare providers. Practice guidelines are unable to account for every individual variation among patients or take the place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must be made by healthcare providers aer consideration of each individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary. 1258 Upsala Rd Sanford, FL 32771 TEL: 407.878.7606 Order additional copies at GuidelineCentral.com Copyright © 2025 All rights reserved ATADTC08253

• Cover